Great Lakes Advisors LLC Has $3.48 Million Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Great Lakes Advisors LLC lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 130.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 379,187 shares of the medical technology company’s stock after buying an additional 214,375 shares during the period. Great Lakes Advisors LLC’s holdings in Alphatec were worth $3,481,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. AlphaQuest LLC acquired a new stake in shares of Alphatec during the 4th quarter worth $80,000. PNC Financial Services Group Inc. grew its holdings in shares of Alphatec by 0.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after purchasing an additional 1,120 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of Alphatec by 93.8% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 44,508 shares of the medical technology company’s stock worth $409,000 after purchasing an additional 21,546 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Alphatec during the 4th quarter worth $358,000. Finally, M&T Bank Corp acquired a new stake in shares of Alphatec during the 4th quarter worth $170,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ATEC shares. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler upped their price objective on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Price Performance

Alphatec stock opened at $9.29 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.34 billion, a PE ratio of -7.26 and a beta of 1.39. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.88. The stock has a 50-day moving average price of $10.95 and a two-hundred day moving average price of $8.70.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity

In other news, CEO Patrick Miles sold 6,687 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the completion of the sale, the chief executive officer now owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. This represents a 0.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 337,321 shares of company stock valued at $3,828,060. Company insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.